Status and phase
Conditions
Treatments
About
To provide open-label entecavir to subjects who have completed previous blinded entecavir trials in Japan and are assessed by the investigator as likely to benefit from additional anti-hepatitis B therapy
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Subjects who completed a previous entecavir Phase II studies (AI463047, 052 or 053);
ALT ≤ 10 x upper limit of normal;
Subjects must have well-compensated liver disease according to ALL of the following criteria;
Exclusion criteria
282 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal